Are Cell and Gene Therapy Innovations Ready for Widespread Use?

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

Treatment of diseases like cancer and HIV is hitting a new frontier with cell-based therapy. This new therapy invigorates the medical world, but it’s not widely accessible yet. Discussing the breakthroughs in these treatments, I Don’t Care host Kevin Stevenson spoke with immunologist Dr. Chris Xu, CEO of ThermoGenesis, a medical device company that’s a pioneer in the field.

“Cell-based therapy came about 13 years ago, and we’ve been fostering the field around cord blood, with 90% of FDA approved cord blood stored in a nitrogen system we developed,” Dr. Xu explained.

That was the company’s beginning, but it has aspirations to do much more. That requires a shift in treatment perspective. “We’ve long used drugs to treat illnesses, but cancer is much more complex. The newly approved therapy takes a patient’s T-cells, which are part of the immune system. It reprograms them to recognize cancer and fight it. It’s the future of medicine,” Dr. Xu said.

“Using someone’s T-cells turns their body into the best defense mechanism against disease.” – Dr. Chris Xu

Thus far, Dr. Xu reported that patients with leukemia and lymphomas have a 93% response rate. He also noted that cancer treatment is just the beginning. Over 1200 trials targeting every type of cancer are ongoing.

HIV is another disease where cell gene therapy has promise. “We discovered that a small percentage of the population doesn’t carry the receptor for HIV, which is necessary for the virus to enter a cell. We can modify cells not to have it, making the patient HIV resistant.”

While the promise of new treatments is here, Dr. Xu noted there are two big impediments. One is cost, with treatments costing as much as $500,000. The other is that patients may no longer have T-cells due to radiation, chemo, or other issues. That’s why he recommends storing cord blood for future use.

Listen to Previous Episodes of I Don’t Care!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

Fiber Deployment
Connected America 2025: Smarter Planning and Partnerships Key to Maximizing Fiber’s Federal Funding and Impact
March 31, 2025

As the digital divide accelerates and fiber deployment sees growth, Connected America 2025 has emerged as a pivotal moment for infrastructure professionals. With over $42.5 billion earmarked through federal programs like the Broadband Equity, Access, and Deployment (BEAD) initiative, the U.S. is undergoing one of the most aggressive broadband expansion efforts in its history….

Read More
Workplace safety
Building a Skilled Trades Workforce: Certifications, Simulation-Based Training & Reskilling with SkillCat
March 31, 2025

Industries across the United States are facing an unprecedented shortage of a skilled trades workforce. With millions of baby boomers retiring and fewer young people entering the trades, sectors like HVAC, manufacturing, and construction are grappling with a critical need for talent. This labor shortage is further compounded by a lack of awareness and…

Read More
K-12 school
Tackling All That K-12 Schools Try to Do: The Solutions
March 31, 2025

As public confidence in major institutions continues to erode, the American K–12 education system finds itself straining under the weight of legacy expectations and modern demands. From grading and college recommendations to extracurriculars and character development, K-12 schools are tasked with a near-impossible mission: to do it all, for everyone. At the same time,…

Read More
wellness
The Rise of AI-Powered Wellness: Vitaquest Taps Big Data to Deliver Personalized Nutrition at Scale
March 31, 2025

The wellness industry is at an inflection point. What once centered around pill packs and generic supplement regimens is now being transformed by an ecosystem of personalization, flavor innovation, and data-driven development. According to research, the global nutraceuticals market is on track to surpass $919 billion by 2030—and with consumer demand increasingly favoring tailored,…

Read More